Perbandingan Efektivitas Klinik Simvastatin dan Atorvastatin Terhadap Profil Lipid Darah: Studi Kasus di Rumah Sakit Universitas Hasanuddin
Main Article Content
Abstract
Simvastatin dan atorvastatin merupakan obat golongan statin yang bekerja dengan menghambat enzim HMG CoA reduktase. Tujuan penelitian ini adalah mengevaluasi efektivitas klinik simvastatin dan atorvastatin dalam mempengaruhi profil lipid darah pasien dislipidemia di Rumah Sakit Universitas Hasanuddin Makassar. Penelitian ini merupakan studi cross sectional menggunakan data rekam medik pasien dislipidemia yang menggunakan simvastatin 10 mg dan atorvastatin 20 mg selama periode 2017-2020. Efektivitas obat golongan statin dinilai dari perubahan nilai LDL, TC, TG, dan HDL sebelum dan setelah penggunaan obat. Analisis regresi linear digunakan untuk menilai perbedaan efek simvastatin dan atorvastatin terhadap parameter lipid darah. Dibandingkan dengan simvastatin, perbedaan efek atorvastatin terhadap nilai LDL, TC, TG dan HDL, berturut-turut adalah 12,11±20,60 (95% Cl: -28,90-53,21), -11,70±11,30 (95% Cl: -14,84-38,24),  -5,02±11,54 (95% Cl: -28,04-18,00) dan 0,42±4,04 (95% Cl: -7,65-8,48). Pasien yang menggunakan atorvastatin memiliki nilai akhir TC, HDL dan TG yang lebih baik dibandingkan simvastatin. Sementara pasien yang menggunakan simvastatin memiliki profil nilai akhir LDL yang lebih baik dibandingkan simvastatin. Hasil analisis statistik menunjukkan perbedaan yang tidak bermakna yang disebabkan karena terbatasnya jumlah pasien. Oleh karena itu, diperlukan studi dengan sampel yang lebih besar untuk melihat perbandingan efektivitas kedua jenis obat statin pada populasi pasien dislipidemia di Indonesia.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
. Soliman GA. Dietary cholesterol and the lack of evidence in cardiovascular disease. Vol. 10, Nutrients. MDPI AG; 2018. https://doi.org/10.3390/nu10060780
. Trapani L, Segatto M, Pallottini V. Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station.†World J Hepatol. 2012;4(6):184–90. https://doi.org/10.4254/wjh.v4.i6.184
. Yuan Y, Chen W, Luo L, Xu C. Dyslipidemia: Causes, Symptoms and Treatment. Int J Trend Sci Res Dev. 2021;5(2):1013–6.
. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J, Hasan S, Thambiah SC. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. Int J Endocrinol Metab. 2017;In Press(In Press). https://doi.org/10.5812/ijem.43319
. Pose E, Trebicka J, Mookerjee RP, Angeli P, Ginès P. Statins: Old drugs as new therapy for liver diseases? Vol. 70, Journal of Hepatology. Elsevier B.V.; 2019. p. 194–202. https://doi.org/10.1016/j.jhep.2018.07.019
. Moorthy NSHN, Cerqueira NMFSA, Ramos MJ, Fernandes PA. Ligand based analysis on HMG-CoA reductase inhibitors. Chemom Intell Lab Syst. 2015;140:102–16. https://doi.org/10.1016/j.chemolab.2014.11.009
. Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, et al. Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovasc Ther. 2020;2020:1–21. https://doi.org/10.1155/2020/3987065
. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Vol. 19, Fundamental and Clinical Pharmacology. 2005. p. 117–25. https://doi.org/10.1111/j.1472-8206.2004.00299.x
. Murphy C, Deplazes E, Cranfield CG, Garcia A. The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins. Int J Mol Sci. 2020;21(22):8745. https://doi.org/10.3390/ijms21228745
. Alsharif NZ, Faulkner MA. Implementation of the Pharmacists’ Patient Care Process in a Medicinal Chemistry Course. Am J Pharm Educ. 2020;84(2):202–12. https://doi.org/10.5688/ajpe7556
. Roche VF. Antihyperlipidemic Statins: A Self-Contained, Clinically Relevant Medicinal Chemistry Lesson. Am J Pharm Educ. 2005;69(4):77. https://doi.org/10.5688/aj690477
. Fernandes JPS. The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist’s Education. Am J Pharm Educ. 2018;82(2):6083. https://doi.org/10.5688/ajpe6083
. Handayani M, Simatupang A. Penggunaan Statin pada Pasien Hiperkolesterolemia. Maj Kedokt UKI. 2019;35(3):96–103.
. Prianwari C, Syafril S. Relationship Between Triglycerides And Glucose Index (TyG) And Lipid Profile In Patients With Dyslipidemia Treated With Bay Leaf Extract (Syzygium Polyanthum (Wight) Walp). J Endocrinol Trop Med Infect Dis. 2020;2(4):177–82. https://doi.org/10.32734/jetromi.v2i4.4778
. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–82. https://doi.org/10.1016/j.jacc.2011.09.067
. Halava H, Helin-Salmivaara A, Junnila J, Huupponen R. Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. Eur J Clin Pharmacol. 2009;65(9):927–33. https://doi.org/10.1007/s00228-009-0664-1
. Dorotea D, Ayumuyas NP, Suprapti B, Wibisono S. The Comparison of Simvastatin and Atorvastatin Efficacy in Lowering Lipid Profile and Apolipoprotein-B of Diabetic Dyslipidemia Patient. Folia Medica Indones. 2013;49(3):139–45.
. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000;5(1):27–32. https://doi.org/10.1177/107424840000500104
. Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006;12:S412–23.
. Althanoon Z, Faisal IM, Ahmad AA, Merkhan MM, Merkhan Pharmacology MM. Pharmacological Aspects of Statins Are Relevant to Their Structural and Physicochemical Properties. Vol. 11, Systematic Reviews in Pharmacy. 2020.
. Ward NC, Watts GF, Eckel RH. Statin Toxicity: Mechanistic Insights and Clinical Implications. Vol. 124, Circulation Research. Lippincott Williams and Wilkins; 2019. p. 328–50. https://doi.org/10.1161/CIRCRESAHA.118.312782